$4.26
1.91% yesterday
Nasdaq, Sep 27, 10:01 pm CET
ISIN
KYG596651029
Symbol
MGTX
Sector
Industry

MeiraGTx Holdings plc Stock price

$4.26
+0.17 4.16% 1M
-1.95 31.40% 6M
-2.76 39.32% YTD
-0.77 15.31% 1Y
-9.33 68.65% 3Y
-11.58 73.11% 5Y
-10.74 71.60% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.08 1.91%
ISIN
KYG596651029
Symbol
MGTX
Sector
Industry

Key metrics

Market capitalization $323.53m
Enterprise Value $311.13m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 38.32
P/S ratio (TTM) P/S ratio 39.84
P/B ratio (TTM) P/B ratio 3.38
Revenue (TTM) Revenue $8.12m
EBIT (operating result TTM) EBIT $-169.20m
Free Cash Flow (TTM) Free Cash Flow $-104.76m
Cash position $99.97m
EPS (TTM) EPS $-1.50
P/E forward negative
P/S forward 10.07
EV/Sales forward 9.68
Short interest 3.24%
Show more

Is MeiraGTx Holdings plc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

MeiraGTx Holdings plc Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a MeiraGTx Holdings plc forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a MeiraGTx Holdings plc forecast:

Buy
100%

Financial data from MeiraGTx Holdings plc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
8.12 8.12
81% 81%
100%
- Direct Costs 14 14
68% 68%
171%
-5.77 -5.77
117% 117%
-71%
- Selling and Administrative Expenses 19 19
40% 40%
231%
- Research and Development Expense 131 131
69% 69%
1,611%
-155 -155
107% 107%
-1,913%
- Depreciation and Amortization 14 14
68% 68%
171%
EBIT (Operating Income) EBIT -169 -169
103% 103%
-2,084%
Net Profit -93 -93
17% 17%
-1,147%

In millions USD.

Don't miss a Thing! We will send you all news about MeiraGTx Holdings plc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

MeiraGTx Holdings plc Stock News

Neutral
GlobeNewsWire
about 2 months ago
- Positive data from the Phase 1 AQUAx study in radiation-induced xerostomia (RIX) presented at the American Academy of Oral Medicine 2024 annual meeting (AAOM) showed meaningful improvements in patient-reported outcomes and saliva production with AAV2-hAQP1 treatment
Neutral
GlobeNewsWire
about 2 months ago
LONDON and NEW YORK, Aug. 12, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicine company, today announced the pricing of an underwritten offering of 12,500,000 of its ordinary shares at an offering price of $4.00 per share. Gross proceeds to MeiraGTx from the offering are expected to be $50 million, before deducting underwriti...
Positive
24/7 Wall Street
about 2 months ago
Penny stocks represent an interesting investment opportunity.
More MeiraGTx Holdings plc News

Company Profile

MeiraGTx Holdings Plc is a clinical-stage biotech company, which engages in the development of novel gene therapy treatments. It operates through the United States and United Kingdom geographical segments. Its pipeline includes AAV-CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR, AAV-AQP1 and AAV-UPF1. The company was founded on March 20, 2015 and is headquartered in New York, NY.

Head office Cayman Islands
CEO Alexandria Forbes
Employees 425
Founded 2015
Website www.meiragtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today